Livzon Pharmac Grp Stock Net Income
| LP6 Stock | EUR 3.02 0.02 0.66% |
As of the 2nd of March, LIVZON PHARMAC secures the Risk Adjusted Performance of (0.01), market risk adjusted performance of (0.51), and Mean Deviation of 2.23. In respect to fundamental indicators, the technical analysis model lets you check practical technical drivers of LIVZON PHARMAC GRP, as well as the relationship between them. Please verify LIVZON PHARMAC GRP mean deviation, standard deviation, information ratio, as well as the relationship between the coefficient of variation and variance to decide if LIVZON PHARMAC GRP is priced more or less accurately, providing market reflects its recent price of 3.02 per share.
LIVZON PHARMAC Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization 2.7 B | Enterprise Value Revenue 1.8004 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Income From Continuing Ops | 2.7 B | 2.2 B | |
| Net Income | 2.4 B | 2.1 B |
LIVZON | Net Income |
The Net Income trend for LIVZON PHARMAC GRP offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether LIVZON PHARMAC is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest LIVZON PHARMAC's Net Income Growth Pattern
Below is the plot of the Net Income of LIVZON PHARMAC GRP over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in LIVZON PHARMAC GRP financial statement analysis. It represents the amount of money remaining after all of LIVZON PHARMAC GRP operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is LIVZON PHARMAC's Net Income historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in LIVZON PHARMAC's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported 2.06 B | 10 Years Trend |
|
Net Income |
| Timeline |
LIVZON Net Income Regression Statistics
| Arithmetic Mean | 1,865,886,403 | |
| Geometric Mean | 1,859,274,583 | |
| Coefficient Of Variation | 9.12 | |
| Mean Deviation | 127,345,626 | |
| Median | 1,775,683,251 | |
| Standard Deviation | 170,114,399 | |
| Sample Variance | 28938.9T | |
| Range | 594.6M | |
| R-Value | 0.73 | |
| Mean Square Error | 14418.9T | |
| R-Squared | 0.53 | |
| Significance | 0.0009 | |
| Slope | 24,591,731 | |
| Total Sum of Squares | 463022.5T |
LIVZON Net Income History
LIVZON PHARMAC 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to LIVZON PHARMAC's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of LIVZON PHARMAC.
| 12/02/2025 |
| 03/02/2026 |
If you would invest 0.00 in LIVZON PHARMAC on December 2, 2025 and sell it all today you would earn a total of 0.00 from holding LIVZON PHARMAC GRP or generate 0.0% return on investment in LIVZON PHARMAC over 90 days. LIVZON PHARMAC is related to or competes with Treasure ASA, MOOG INC, Biotest Aktiengesellscha, Uniper SE, and Uniper SE. Livzon Pharmaceutical Group Inc. engages in the research, development, production, and distribution of pharmaceutical pr... More
LIVZON PHARMAC Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure LIVZON PHARMAC's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess LIVZON PHARMAC GRP upside and downside potential and time the market with a certain degree of confidence.
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 15.54 | |||
| Value At Risk | (6.43) | |||
| Potential Upside | 6.62 |
LIVZON PHARMAC Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for LIVZON PHARMAC's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as LIVZON PHARMAC's standard deviation. In reality, there are many statistical measures that can use LIVZON PHARMAC historical prices to predict the future LIVZON PHARMAC's volatility.| Risk Adjusted Performance | (0.01) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.43) | |||
| Treynor Ratio | (0.52) |
LIVZON PHARMAC March 2, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | (0.01) | |||
| Market Risk Adjusted Performance | (0.51) | |||
| Mean Deviation | 2.23 | |||
| Coefficient Of Variation | (4,055) | |||
| Standard Deviation | 3.29 | |||
| Variance | 10.82 | |||
| Information Ratio | (0.05) | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.43) | |||
| Treynor Ratio | (0.52) | |||
| Maximum Drawdown | 15.54 | |||
| Value At Risk | (6.43) | |||
| Potential Upside | 6.62 | |||
| Skewness | 0.2598 | |||
| Kurtosis | 0.7705 |
LIVZON PHARMAC GRP Backtested Returns
LIVZON PHARMAC GRP has Sharpe Ratio of -0.0295, which conveys that the firm had a -0.0295 % return per unit of standard deviation over the last 3 months. LIVZON PHARMAC exposes twenty-one different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please verify LIVZON PHARMAC's Mean Deviation of 2.23, market risk adjusted performance of (0.51), and Risk Adjusted Performance of (0.01) to check out the risk estimate we provide. The company secures a Beta (Market Risk) of 0.18, which conveys not very significant fluctuations relative to the market. As returns on the market increase, LIVZON PHARMAC's returns are expected to increase less than the market. However, during the bear market, the loss of holding LIVZON PHARMAC is expected to be smaller as well. At this point, LIVZON PHARMAC GRP has a negative expected return of -0.0958%. Please make sure to verify LIVZON PHARMAC's potential upside, kurtosis, day median price, as well as the relationship between the skewness and rate of daily change , to decide if LIVZON PHARMAC GRP performance from the past will be repeated at future time.
Auto-correlation | 0.20 |
Weak predictability
LIVZON PHARMAC GRP has weak predictability. Overlapping area represents the amount of predictability between LIVZON PHARMAC time series from 2nd of December 2025 to 16th of January 2026 and 16th of January 2026 to 2nd of March 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of LIVZON PHARMAC GRP price movement. The serial correlation of 0.2 indicates that over 20.0% of current LIVZON PHARMAC price fluctuation can be explain by its past prices.
| Correlation Coefficient | 0.2 | |
| Spearman Rank Test | 0.1 | |
| Residual Average | 0.0 | |
| Price Variance | 0.01 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
LIVZON Net Interest Income
Net Interest Income |
|
Based on the recorded statements, LIVZON PHARMAC GRP reported net income of 2.06 B. This is much higher than that of the Pharmaceuticals sector and significantly higher than that of the Health Care industry. The net income for all Germany stocks is significantly lower than that of the firm.
LIVZON Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses LIVZON PHARMAC's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of LIVZON PHARMAC could also be used in its relative valuation, which is a method of valuing LIVZON PHARMAC by comparing valuation metrics of similar companies.LIVZON PHARMAC is currently under evaluation in net income category among its peers.
LIVZON Fundamentals
| Return On Equity | 0.16 | ||||
| Return On Asset | 0.0638 | ||||
| Profit Margin | 0.18 % | ||||
| Operating Margin | 0.25 % | ||||
| Current Valuation | 2.64 B | ||||
| Shares Outstanding | 299.81 M | ||||
| Shares Owned By Insiders | 54.40 % | ||||
| Shares Owned By Institutions | 12.69 % | ||||
| Price To Earning | 4.02 X | ||||
| Price To Book | 1.55 X | ||||
| Price To Sales | 0.23 X | ||||
| Revenue | 11.81 B | ||||
| Gross Profit | 7.64 B | ||||
| EBITDA | 2.87 B | ||||
| Net Income | 2.06 B | ||||
| Cash And Equivalents | 1.14 B | ||||
| Cash Per Share | 1.58 X | ||||
| Total Debt | 2.46 B | ||||
| Debt To Equity | 1.30 % | ||||
| Current Ratio | 2.60 X | ||||
| Book Value Per Share | 1.95 X | ||||
| Cash Flow From Operations | 2.98 B | ||||
| Earnings Per Share | 0.30 X | ||||
| Number Of Employees | 9.07 K | ||||
| Beta | 0.37 | ||||
| Market Capitalization | 2.68 B | ||||
| Total Asset | 24.46 B | ||||
| Retained Earnings | 11.76 B | ||||
| Working Capital | 8.79 B | ||||
| Annual Yield | 0.04 % | ||||
| Net Asset | 24.46 B | ||||
| Last Dividend Paid | 1.1 |
About LIVZON PHARMAC Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze LIVZON PHARMAC GRP's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of LIVZON PHARMAC using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of LIVZON PHARMAC GRP based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Other Information on Investing in LIVZON Stock
LIVZON PHARMAC financial ratios help investors to determine whether LIVZON Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in LIVZON with respect to the benefits of owning LIVZON PHARMAC security.